Literature DB >> 2782975

Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months.

V Kyle1, B L Hazleman.   

Abstract

Thirty nine patients with polymyalgia rheumatica (PMR) and 35 with giant cell arteritis (GCA) were treated with high or low dose steroid regimens in a prospective study of the first two months of treatment. Patients with PMR needed 15-20 mg prednisolone initially; 13/20 (65%) relapsed on an initial dose of 10 mg/day. All but two patients with GCA were successfully treated with 40 mg/day prednisolone initially but relapsed on a reduction to 20 mg/day. One patient with GCA receiving 30 mg/day relapsed after four weeks. Six patients with PMR developed GCA during the first two months and required an increased prednisolone dose to control symptoms. The erythrocyte sedimentation rate or C reactive protein did not predict relapse.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2782975      PMCID: PMC1003842          DOI: 10.1136/ard.48.8.658

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  21 in total

1.  TEMPORAL ARTERITIS.

Authors:  A G WHITFIELD; M BATEMAN; W T COOKE
Journal:  Br J Ophthalmol       Date:  1963-09       Impact factor: 4.638

2.  Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects.

Authors:  V Kyle; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

3.  Observations on temporal arteritis.

Authors:  B Wadman; I Werner
Journal:  Acta Med Scand       Date:  1972-11

Review 4.  Giant cell arteritis: including temporal arteritis and polymyalgia rheumatica.

Authors:  C R Hamilton; W M Shelley; P A Tumulty
Journal:  Medicine (Baltimore)       Date:  1971-01       Impact factor: 1.889

5.  Polymyalgia rheumatica and its relation to arteritis temporalis.

Authors:  O A Kogstad
Journal:  Acta Med Scand       Date:  1965-11

6.  Neurological complications of connective tissue and other "collagen-vascular" diseases.

Authors:  S B Cohen; E R Hurd
Journal:  Semin Arthritis Rheum       Date:  1981-08       Impact factor: 5.532

7.  Polymyalgia rheumatica: a 10-year epidemiologic and clinical study.

Authors:  T Y Chuang; G G Hunder; D M Ilstrup; L T Kurland
Journal:  Ann Intern Med       Date:  1982-11       Impact factor: 25.391

8.  Polymyalgia rheumatica and corticosteroids: how much for how long?

Authors:  A R Behn; T Perera; A B Myles
Journal:  Ann Rheum Dis       Date:  1983-08       Impact factor: 19.103

9.  [Rhizomelic pseudopolyarthritis].

Authors:  A Hubault
Journal:  Presse Med       Date:  1983-01-22       Impact factor: 1.228

10.  Polymyalgia rheumatica. Duration of therapy and long-term outcome.

Authors:  W T Ayoub; C M Franklin; D Torretti
Journal:  Am J Med       Date:  1985-09       Impact factor: 4.965

View more
  29 in total

1.  Giant Cell Arteritis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-03       Impact factor: 3.598

2.  Giant cell arteritis.

Authors:  J C Mason; M J Walport
Journal:  BMJ       Date:  1992-07-11

3.  EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

Authors:  J N Hoes; J W G Jacobs; M Boers; D Boumpas; F Buttgereit; N Caeyers; E H Choy; M Cutolo; J A P Da Silva; G Esselens; L Guillevin; I Hafstrom; J R Kirwan; J Rovensky; A Russell; K G Saag; B Svensson; R Westhovens; H Zeidler; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-07-27       Impact factor: 19.103

4.  Treatment of polymyalgia rheumatica and giant cell arteritis.

Authors:  M T Watts; M E Nelson; I G Rennie
Journal:  Ann Rheum Dis       Date:  1990-07       Impact factor: 19.103

Review 5.  Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.

Authors:  Jean Schmidt; Kenneth J Warrington
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

6.  Polymyalgia rheumatica and giant cell arteritis. High dose corticosteroids are recommended.

Authors:  J Ferris; R Lamb
Journal:  BMJ       Date:  1995-08-12

7.  Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects.

Authors:  V Kyle; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

Review 8.  [Diagnostics and treatment of polymyalgia rheumatica].

Authors:  C Dejaco; E L Matteson; F Buttgereit
Journal:  Z Rheumatol       Date:  2016-09       Impact factor: 1.372

Review 9.  Giant cell arteritis. Epidemiology and treatment.

Authors:  E Nordborg; R Andersson; B A Bengtsson
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

10.  Treatment of polymyalgia rheumatica with intramuscular injections of depot methylprednisolone.

Authors:  B Dasgupta; J Gray; L Fernandes; C Olliff
Journal:  Ann Rheum Dis       Date:  1991-12       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.